Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学Ovarian Cancer

Michael Friedlander

迈克尔·弗里德兰德

MD, FRACP, FRCPA

🏢University of New South Wales (UNSW) Sydney / Prince of Wales Hospital(新南威尔士大学/威尔士亲王医院)🌐Australia

Professor of Medical Oncology; Head, Gynaecological Oncology Clinical Research肿瘤内科学教授;妇科肿瘤临床研究主任

55
h-index
2
Key Papers
3
Awards
2
Key Contributions

👥Biography 个人简介

Michael Friedlander, MD, FRACP is a Professor of Medical Oncology at UNSW Sydney and a leading figure in Australian and international gynecologic oncology. He has contributed extensively to chemotherapy optimization and PARP inhibitor trials in ovarian cancer, and serves on multiple GCIG and ANZGOG steering committees.

Share:

🧪Research Fields 研究领域

Ovarian Cancer卵巢癌
PARP InhibitorsPARP抑制剂
Chemotherapy Optimization化疗方案优化
Platinum-Sensitive Recurrence铂敏感复发
Biomarker-Driven Clinical Trials生物标志物驱动临床试验

🎓Key Contributions 主要贡献

PARP Inhibitor and Chemotherapy Trials in Ovarian Cancer

Contributed to multiple international PARP inhibitor phase III trials and chemotherapy optimization studies, helping to define optimal sequencing and combination strategies in platinum-sensitive and resistant ovarian cancer.

ANZGOG Leadership and Asia-Pacific Clinical Trial Development

Led the Australia New Zealand Gynaecological Oncology Group (ANZGOG) in developing and conducting investigator-initiated trials, expanding evidence for novel therapies in the Asia-Pacific region.

Representative Works 代表性著作

[1]

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer (ICON3)

The Lancet (2002)

Major ICON3 trial contribution examining paclitaxel-carboplatin versus alternative regimens, informing standard chemotherapy regimens for ovarian cancer.

[2]

Niraparib maintenance therapy in Asian patients with platinum-sensitive recurrent ovarian cancer (NORA trial results in Asia-Pacific context)

Annals of Oncology (2022)

Contributed to PARP inhibitor maintenance efficacy and safety data relevant to Asia-Pacific populations with platinum-sensitive recurrent ovarian cancer.

🏆Awards & Recognition 奖项与荣誉

🏆Australia New Zealand Gynaecological Oncology Group Distinguished Investigator Award
🏆GCIG Scientific Achievement Award
🏆Cancer Institute NSW Research Excellence Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 迈克尔·弗里德兰德 的研究动态

Follow Michael Friedlander's research updates

留下邮箱,当我们发布与 Michael Friedlander(University of New South Wales (UNSW) Sydney / Prince of Wales Hospital)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment